Rivaroxaban (Xarelto), a competitive inhibitor of factor Xa, was first approved by the FDA after its study in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial [40]. The gene discussed is F10; the disease is stroke disorder.